Dulaglutide
Also known as: Trulicity · LY2189265
A once-weekly GLP-1 receptor agonist FDA-approved for Type 2 diabetes with cardiovascular risk reduction. Engineered with monoclonal antibody technology.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
~5 days
0.75–4.5 mg weekly
Subcutaneous injection
Mechanism of Action
GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended duration, enhancing glucose-dependent insulin secretion and reducing cardiovascular risk.
Key Research Areas
Frequently Asked Questions
What is Dulaglutide?▾
How does Dulaglutide work?▾
What is the recommended dosage for Dulaglutide?▾
What is the half-life of Dulaglutide?▾
Is Dulaglutide FDA approved?▾
Research Disclaimer
The information provided about Dulaglutide is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.